Sort
48,018 grants matching “immunotherapy”
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
$659,516Estuardo Aguilar-Cordova · Advantagene, Inc · R44 · FY2018 · CA
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1
$659,506Pawel Kalinski · Roswell Park Cancer Institute Corp · P50 · FY2017 · CA
Develop lung-targeted synthetic lipid nanoparticles for mRNA medicine treating pulmonary lymphangioleiomyomatosis
$659,481Qiaobing Xu · Tufts University Medford · R01 · FY2024 · HL
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials
$659,371Andre Rogatko · Cedars-Sinai Medical Center · U01 · FY2019 · CA
Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy
$659,355Sonia Sharma · La Jolla Institute For Immunology · R01 · FY2024 · CA
Neuro-immune mechanisms in mutant IDH1 gliomas
$659,325Maria G Castro · University Of Michigan At Ann Arbor · R37 · FY2025 · NS
Nanoscale programming of celluar and physiological phenotypes
$659,274Nikolay V Dokholyan · University Of Virginia · R35 · FY2025 · GM
Targeting posttranslational modifications of CD73 in TNBCs
$659,221Yong Wan · Northwestern University At Chicago · R01 · FY2021 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$659,220Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2023 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$659,220Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2022 · CA
DEVELOPMENT OF PRECISION IMMUNOTHERAPY FOR ADVANCED PROSTATE CANCER
$659,099Fred Hutchinson Cancer Research Center · · FY2015 · Department of Defense
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
$659,051Manish Bais · Boston University Medical Campus · R01 · FY2023 · DE
Molecular, Cellular and Genetic Analyses of Malignancies Associated with NF1
$659,046Karlyne M Reilly · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
$658,974Michael T Lewis · Baylor College Of Medicine · U24 · FY2019 · CA
Epigenetic Therapy for Thoracic Malignancies
$658,967David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2020 · CA
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local Immunotherapy
$658,892Simon Young · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · DE
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy
$658,891Youngho Seo · University Of California, San Francisco · R01 · FY2025 · HL
Signal transduction and gene induction in lymphocytes
$658,800Patrick Hogan · La Jolla Institute For Immunology · R01 · FY2024 · AI
Signal transduction and gene induction in lymphocytes
$658,800Patrick Hogan · La Jolla Institute For Immunology · R01 · FY2023 · AI
Predicting trajectories of function, cognition, and quality of life among older adults with advanced lung cancer
$658,743Melisa L Wong · Kaiser Foundation Research Institute · R37 · FY2025 · CA
Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer Therapy
$658,727Eric C. Frey · Johns Hopkins University · U01 · FY2015 · CA
Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$658,720David E Fisher · Massachusetts General Hospital · P01 · FY2024 · CA
Novel approaches to target KEAP1 mutant tumors
$658,687Thales Papagiannakopoulos · New York University School Of Medicine · R01 · FY2025 · CA
Integrating Epigenetic Modulation into DNA Damage Repair
$658,646Pamela N Munster · University Of California, San Francisco · R01 · FY2025 · CA
Targeted MDM2 degradation for improved treatment for triple-negative breast cancer
$658,561Wei Li · University Of Tennessee Health Sci Ctr · R01 · FY2025 · CA